利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.017 秒)

    CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
    2.
    发明申请
    CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE 有权
    中枢神经系统药物组合物及其使用方法

    公开(公告)号：US20110054038A1

    公开(公告)日：2011-03-03

    申请号：US12860846

    申请日：2010-08-20

    申请人： Sabina Glozman

    发明人： Sabina Glozman

    IPC分类号： A61K31/138 ,  A61K31/09 ,  A61P25/00

    CPC分类号： A61K31/09 ,  A61K31/138

    摘要： The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy/activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and/or released.

    摘要翻译： 本发明涉及CNS药物组合物和使用方法。 药物组合物包含CNS活性剂，优选至少两种迷走神经调节剂，其中之一是机械受体刺激剂。 迷走神经调节剂优选以足以降低CNS活性剂的嗜睡副作用而不改变其治疗功效/活性的量。 本发明还包括减少CNS活性剂副作用的方法。 该方法通常包括以常规接受的剂量向患者口服至少一种CNS活性剂; 以及向患者施用至少两种迷走神经调节剂，使得在CNS活性剂被施用和/或释放之后至少一种神经调节剂从剂型施用或释放。

    Compositions and Methods for Inhibiting Gastric Acid Secretion
    3.
    发明申请
    Compositions and Methods for Inhibiting Gastric Acid Secretion 有权
    抑制胃酸分泌的组合物和方法

    公开(公告)号：US20100247634A1

    公开(公告)日：2010-09-30

    申请号：US12768375

    申请日：2010-04-27

    申请人： Aleksey Kostadinov ,  Ayelet David ,  Sabina Glozman

    发明人： Aleksey Kostadinov ,  Ayelet David ,  Sabina Glozman

    IPC分类号： A61K9/48 ,  A61K9/20 ,  A61K9/28 ,  A61K31/19 ,  A61K31/194

    CPC分类号： A61K31/19 ,  A61K9/2081 ,  A61K31/4439 ,  A61K47/12 ,  A61K2300/00

    摘要： The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.

    摘要翻译： 本发明涉及包含作为胃酸分泌抑制剂的不可逆胃H + / K + -ATP酶质子泵抑制剂（PPI）和作为胃内腔壁细胞活化剂的一种或多种小羧酸分子的新型口服组合物。 意外地，本发明的组合物能够增强胃中PPI的抗酸活性。 本发明还涉及使用这种组合物以减少哺乳动物胃酸分泌的方法。

    Methods for treatment of Helicobacter pylori-associated disorders
    4.
    发明授权
    Methods for treatment of Helicobacter pylori-associated disorders 失效
    治疗幽门螺杆菌相关疾病的方法

    公开(公告)号：US07271146B2

    公开(公告)日：2007-09-18

    申请号：US10682937

    申请日：2003-10-14

    申请人： Sabina Glozman

    发明人： Sabina Glozman

    IPC分类号： A61K38/00 ,  A61K49/00

    CPC分类号： A61K31/4439 ,  A61K38/2207 ,  A61K2300/00

    摘要： The present invention relates to methods for treating pathological conditions associated with Helicobacter sp infections, specifically H. pylori infection. The present invention further relates to methods for treating pathologies characterized by excess gastric acid secretion. The methods of the present invention comprise oral administration of pentagastrin effective locally in the stomach in conjunction with a gastric proton pump inhibitor. It is disclosed herein for the first time that PG administered orally exerts a local effect in the stomach and may be used in combination with a PPI for treating pathological conditions characterized by excess gastric acid secretion and in pathological conditions associated with Helicobacter sp infections.

    摘要翻译： 本发明涉及用于治疗与幽门螺杆菌感染，特别是幽门螺杆菌感染相关的病理状况的方法。 本发明还涉及以过量胃酸分泌为特征的治疗病态的方法。 本发明的方法包括与胃质子泵抑制剂联合在胃部局部施用五加胃泌素的口服给药。 本文首次公开了口服给药的PG在胃中发挥局部作用，并且可以与PPI组合使用，用于治疗特征在于过量胃酸分泌的病理状况以及与幽门螺杆菌感染相关的病理状况。

    Oral compositions for the stimulation of gastric acid secretion comprising pentagastrin
    5.
    发明申请
    Oral compositions for the stimulation of gastric acid secretion comprising pentagastrin 审中-公开
    用于刺激胃酸分泌的口服组合物，其包含五肽胃泌素

    公开(公告)号：US20060172004A1

    公开(公告)日：2006-08-03

    申请号：US11378187

    申请日：2006-03-17

    申请人： Sabina Glozman

    发明人： Sabina Glozman

    IPC分类号： A61K38/17 ,  A61K9/48 ,  A61K9/20

    CPC分类号： A61K9/2054 ,  A61K9/0007 ,  A61K9/1676 ,  A61K9/2009 ,  A61K9/2059 ,  A61K9/485 ,  A61K9/4866 ,  A61K9/5084 ,  A61K38/2207

    摘要： The present invention discloses oral compositions comprising pentagastrin (PG) as an effective diagnostic agent for gastric acid secretion. The composition further comprises one or more agents that preserve the availability of PG in the gastric fluids, so that the biological activity of PG is maintained. The pharmaceutical compositions according to the present invention can be applied as diagnostic agents in the determination of the maximum gastric acid secretion as well as therapeutics.

    摘要翻译： 本发明公开了包含五肽胃泌素（PG）作为胃酸分泌的有效诊断剂的口服组合物。 组合物还包含一种或多种保持胃液中PG的可用性的试剂，从而维持PG的生物活性。 根据本发明的药物组合物可以用作诊断剂，以确定最大胃酸分泌以及治疗剂。

    CNS pharmaceutical compositions and methods of use
    7.
    发明授权
    CNS pharmaceutical compositions and methods of use 有权
    CNS药物组合物和使用方法

    公开(公告)号：US08729070B2

    公开(公告)日：2014-05-20

    申请号：US12860846

    申请日：2010-08-20

    申请人： Sabina Glozman

    发明人： Sabina Glozman

    IPC分类号： A61K31/55 ,  A61K31/155 ,  A61K33/30 ,  A61K31/19

    CPC分类号： A61K31/09 ,  A61K31/138

    摘要： The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy/activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and/or released.

    摘要翻译： 本发明涉及CNS药物组合物和使用方法。 药物组合物包含CNS活性剂，优选至少两种迷走神经调节剂，其中之一是机械受体刺激剂。 迷走神经调节剂优选以足以降低CNS活性剂的嗜睡副作用而不改变其治疗功效/活性的量。 本发明还包括减少CNS活性剂副作用的方法。 该方法通常包括以常规接受的剂量向患者口服至少一种CNS活性剂; 以及向患者施用至少两种迷走神经调节剂，使得在CNS活性剂被施用和/或释放之后至少一种神经调节剂从剂型施用或释放。